Cochrane · systematic review · CD013817
Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension
Clement Freiberg, J, von Spreckelsen, A, Kolko, M, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
12
No studies
30
Included studies
NR
No studies 30 · 71.4%Ungraded 0 · 0%Very low 1 · 2.4%Low 5 · 11.9%Moderate 6 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rho kinase inhibitor compared to placeboa
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor vs placeboa | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor vs placeboa | no estimate extracted | 3 studies · 155 participants | Low Downgraded: risk of bias, imprecision |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriad Rho kinase inhibitor vs placeboa | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor vs placeboa | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor vs placeboa | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor vs placeboa | no estimate extracted | NR | No studies |
Average number of ocular adverse events at the longest Rho kinase inhibitor vs placeboa | no estimate extracted | 4 studies · 188 participants | Very low Downgraded: risk of bias, imprecision |
Rho kinase inhibitor compared to beta‐blocker
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor vs beta‐blocker | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor vs beta‐blocker | no estimate extracted | 3 studies · 1415 participants | Low Downgraded: risk of bias |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab Rho kinase inhibitor vs beta‐blocker | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor vs beta‐blocker | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor vs beta‐blocker | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor vs beta‐blocker | no estimate extracted | NR | No studies |
Number of ocular adverse events at the longest Rho kinase inhibitor vs beta‐blocker | no estimate extracted | 4 studies · 1678 participants | Moderate Downgraded: risk of bias |
Rho kinase inhibitor compared to prostaglandin analog
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | 4 studies · 1283 participants | Moderate Downgraded: risk of bias |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | NR | No studies |
Number of ocular adverse events at the longest Rho kinase inhibitor vs prostaglandin analog | no estimate extracted | 4 studies · 1286 participants | Low Downgraded: risk of bias |
Rho kinase inhibitor and prostaglandin analog compared to prostaglandin analoga
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | 3 studies · 1114 participants | Moderate Downgraded: inconsistency |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | NR | No studies |
Number of ocular adverse events at the longest Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga | no estimate extracted | 4 studies · 1321 participants | Low |
Rho kinase inhibitor and prostaglandin analog compared to rho kinase inhibitor
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | 3 studies · 1132 participants | Moderate Downgraded: risk of bias |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | NR | No studies |
Number of ocular adverse events at the longest Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor | no estimate extracted | 3 studies · 1131 participants | Low Downgraded: risk of bias |
Rho kinase inhibitor and beta‐blocker compared to beta‐blocker
Population: people with primary open‐angle glaucoma or ocular hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Glaucoma progression at 12 months, measured by additional visual field defects Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | NR | No studies |
Difference in mean IOP from baseline at < 6 months Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | 1 study · 208 participants | Moderate Downgraded: imprecision |
Glaucoma progression at 12 months, defined by anatomic (structural) criteriab Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | NR | No studies |
Patient‐reported outcome at the longest Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | NR | No studies |
Mean change in the number of glaucoma medications at the longest Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | NR | No studies |
Need for additional treatment at the longest Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | NR | No studies |
Number of ocular adverse events at the longest Rho kinase inhibitor and beta‐blocker vs beta‐blocker | no estimate extracted | 1 study · 208 participants | Moderate Downgraded: imprecision |